Comparison
SNAP-8 vs. Survodutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Cosmetic
Metabolic
CAS no.
868844-74-0
2179963-22-7
Molecular weight
1075.16 g/mol
4727 g/mol
Half-life
no data
168 h
Sequence
Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2modifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteMechanism of action
SNAP-8
SNAP-8 is an octapeptide variant of Argireline. The sequence corresponds to the N-terminus of the SNAP-25 protein. As with Argireline, the postulated mechanism is competitive inhibition of the SNARE complex needed for acetylcholine vesicle fusion at the neuromuscular endplate. According to the manufacturer the two extra C-terminal amino acids increase SNARE-complex affinity — there are individual industry studies on this but no independent systematic confirmation.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
3
2
of which in humans
1
2
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
1
2